Business Wire

FOURKITES

6.2.2024 07:25:29 CET | Business Wire | Press release

Share
Updates to FourKites' Dynamic Ocean Help Customers Quickly Mitigate Disruptions and Combat Fees with Greater Accuracy

Leading supply chain visibility provider FourKites® today announced several enhancements to Dynamic Ocean®, its next-generation ocean visibility solution. By providing better context, clarity and control throughout every ocean shipment, these new features help FourKites users worldwide mitigate disruptions, including conflict on the Red Sea and low water levels in the Panama Canal; reduce costly fees like preventable detention and demurrage charges; and exceed customer expectations.

“Adding FourKites’ ocean visibility to our technology stack was an obvious choice, and it has paid off handsomely,” said Davide Busato, Logistic Competence Center Innovation Project Manager at Barilla. “Now we don’t need to spend time hunting for answers and instead can focus on more important tasks like acting on the FourKites data to improve customer satisfaction.”

Dynamic Ocean leverages multilayered data to provide a robust, dependable and continuous picture of the end-to-end supply chain. With FourKites latest releases, supply chain managers can make the right decisions quickly when unexpected disruptions arise.

Specifically, new enhancements to Dynamic Ocean include:

  • Improved Dynamic ETAs and ETDs that deliver 95%+ accuracy for ETAs to the final destination; 90%+ accuracy for vessel arrival terminal predictions; and synchronised ETAs and ETDs for multiple shipments on the same vessel. FourKites ETAs are 27-37% more accurate than carrier ETAs, on average.
  • Improved data quality and latency, enabling 85% of events to be provided within 8 hours of their occurrence, which is 35% faster than industry standards. FourKites Visibility and ETAs are based on multilayered, resilient data, giving customers a robust and continuous picture of their end-to-end supply chain.
  • Earlier, more precise alerts that help customers proactively identify exceptions — as well as containers incurring detention and demurrage fees — to reduce risk, minimise costs and boost customer satisfaction.
  • A seamless, end-to-end user interface that eliminates silos for international teams so they can avoid fines and fees, provide smoother handoffs with collaborators, and improve customer satisfaction.

With these updates, FourKites customers will continue to root out unnecessary costs and waste in their supply chain.

“Our goals with FourKites in 2024 are to track 90% of our shipments, reduce penalties with carriers by 5% and decrease inefficient communication with partners by 10-15%,” added Busato. “Thanks to FourKites’ ability to send automatic ETAs with delay updates, among other features, we’re well on our way to meeting these metrics.”

FourKites’ new ocean features also include an improved detention and demurrage dashboard and analytics to help customers reduce penalties tied to delays, manage carrier performance, and analyse cost and service levels by lane. Moreover, a real-time view of inbound inventory empowers companies to optimise safety stock and working capital, accelerate inventory turnover and delight customers through visibility-enhanced order processing, fulfillment, invoicing and collection.

Powering these enhancements is FourKites’ deep trove of supply chain data such as schedule data on 11,000+ ocean lanes and data and integrations for 100+ carriers and 3,000+ services. In addition, FourKites provides detailed in-port tracking and congestion data at 150+ major global ocean terminals.

“In the face of military conflict in the Red Sea, storms and supply shortages, end-to-end visibility is critical to resilient ocean supply chains. And when disruptions do occur, minutes matter,” says Priya Rajagopalan, Chief Product Officer at FourKites. “With our enhancements to ocean visibility, FourKites is giving cross-functional teams access to the real-time supply chain data and insights they need — helping them seamlessly integrate their international supply chain and keep their customers happy.”

Enhancements to FourKites Dynamic Ocean are available starting today. For more information, visit https://www.fourkites.com/platform/ocean-freight-visibility/.

About FourKites

Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3.2 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240205928770/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye